Navigation Links
Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
Date:1/30/2008


2008 Projected Financial Highlights and Potential Milestones include:

- Grow Zevalin sales

- XYOTAX(TM) Marketing Authorization Application submission in Q1

- Pixantrone phase III results and New Drug Application submission

- Brostallicin phase II interim results

SEATTLE, Jan. 30 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that with the return of CTI to a commercial operating company through its acquisition of Zevalin(R) (Ibritumomab Tiuxetan), the company will focus its resources on increasing the sales of Zevalin in the United States and preparing the marketing applications for XYOTAX (paclitaxel poliglumex, CT-2103) and pixantrone (BBR 2778), while supporting the advancement of brostallicin to a phase III trial. The move will reduce the Company's projected net cash operating expenses to a forecasted $77 million in 2008. The primary reduction in operating expenses stems from deferring or curtailing some phase III clinical trials for pixantrone and XYOTAX until planned regulatory filings and the completion of phase III studies result in product approvals. CTI expects to file for approval of XYOTAX in Europe in March. The Company will expand its commercial infrastructure for Zevalin and possible future drug sales while achieving an overall reduction in headcount.

"We believe the best way to maximize shareholder value now is to focus our resources on our marketed and late-stage products," noted James A. Bianco, M.D., President and CEO of CTI.

"Recently published data describing the clinical benefit of Zevalin are compelling and support the potential to expand its application into first-line treatment of follicular non-Hodgkin's lymphoma, leading us to expand our commercial operations staffing from 11 percent to 21 percent of our total headcount with corresponding reductions elsewhere. We will continue to support our two lead drug candidates, XYOTAX
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. Announces $6.5 Million Offering
4. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
5. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
6. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
9. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
10. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... ODU , a worldwide ... solutions and cable assemblies, is announcing its highly ... US market. , ODU MINI-SNAP® is ... self- securing circular connector solution is ideal for ... significant customization such as: sensor devices, data collecting ...
(Date:6/2/2015)... PhishLine, LLC today announced it ... Drive, Suite 125 in Waukesha, Wisconsin 53186. ... base of operations for PhishLine’s current corporate staff ... , Mark Chapman, Founder and President, commented “PhishLine ... enterprise customers adopt our market leading service to ...
(Date:6/2/2015)... 2015 The Non-GMO Project offers ... made according to rigorous best practices for GMO ... in compliance with the Non-GMO Project Standard - ... ingredients, facility inspections and an annual audit to ... , “Savoury Systems is and has always been ...
(Date:6/2/2015)... TheCelebrityDresses.com, a popular online store selling celebrity inspired ... fashion cocktail dresses. The company carries more than 1000 ... suitable for a wide variety of summer events like ... make high quality trendy special occasion dresses ... satin, chiffon and cotton. Their products feature a wide ...
(Date:6/2/2015)... 02, 2015 TranSlice: Reveal from Pixel Film ... TranSlice: Reveal allows Final Cut Pro X users to transition ... reveal their next screen. , TranSlice Reveal brings back the ... Cut Pro X users can now transition from one ... With every panel orientation and direction covered, no transition will ...
Breaking Medicine News(10 mins):Health News:ODU Announces ODU MINI-SNAP® - Advanced Circular Connector Solution for Highly Customizable Applications 2Health News:PhishLine, LLC Announces New Corporate Headquarters 2Health News:Savoury Systems International Receives Non-GMO Project Verification Continuing its Commitment to Provide Customers with Clean Label Ingredients 2Health News:Announcing the release of TranSlice Reveal from Pixel Film Studios - Professional Split Screen Transitions for FCPX. 2
... Senator Norm Coleman, Deputy HHS Secretary Tevi ... patient and medical community participate in a conference to, ... Preventive, Services Task Force report dismissing the vital role ... The Potomac,Institute for Policy Studies and the Glaucoma Foundation ...
... Although all cancers are not alike, most share common ... mutation or faulty biochemical signaling pathway. For that reason, ... impact on many others. Increasingly, researchers are discovering ways ... broadening the targets of already-approved targeted therapeutics. ...
... for more accurately determining the composition of medicines. ... techniques that were previously considered to be incompatible: ... detection technique mass spectroscopy (MS). He has used ... mechanism for the active ingredient and excipients in ...
... fool Mother Nature, experts say , , WEDNESDAY, Oct. 24 (HealthDay ... an hour more of sunlight, but it appears that their ... researchers report. , In fact, daylight savings time can cause ... our bodies, according to the report in the Oct. 24 ...
... Oct. 24 In a pioneering effort, Children,s,Hospital ... Pittsburgh School of,Medicine have joined forces to launch ... field of pediatric research. The potential of ... Mellon Foundation through a groundbreaking gift of $23 ...
... of ... ARLINGTON, Va., Oct. 24 Vangent, Inc., a leading,provider ... leading expert in governmental healthcare programs and member,eligibility, today ... services to redeem members who recently received letters,from the ...
Cached Medicine News:Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 2Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 3Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 4Health News:Chair of U.S. Preventive Services Task Force Pledges to Recommend Re-evaluation of Recent Glaucoma Findings 5Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 2Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 3Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 4Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 5Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 6Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 7Health News:A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks 8Health News:New technique improves purity of medicines 2Health News:Body's Clock Never Adjusts to Daylight Savings Time 2Health News:Body's Clock Never Adjusts to Daylight Savings Time 3Health News:Collaboration to Create Pediatric Research Institute Receives $23 Million 2Health News:Collaboration to Create Pediatric Research Institute Receives $23 Million 3Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 2Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 3Health News:Vangent and Human Arc Win Business With 13 Medicare Part D Plans 4
(Date:6/1/2015)... , June 1, 2015  Research Solutions, Inc. (OTCQB: ... and medical (STM) information for life science companies, academic ... to present at the LD Micro Invitational being held ... in Los Angeles . ... on Wednesday, June 3rd at 9:30 a.m. Pacific time, ...
(Date:6/1/2015)...  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) today announced ... ,nal-IRI, in a Phase 1 investigator-sponsored study at the ... were presented at the 2015 American Society of Clinical ... Results from this study show a tolerable ... when given intravenously.  Based in part on ...
(Date:6/1/2015)... 2015 About Pressure Relief ... area and improve the quality life of patients who ... play a significant role in inhibiting the growth and ... to turn or rotate an immobile patient by providing ... overlay, and specialty beds. These devices have the ability ...
Breaking Medicine Technology:Research Solutions to Present at the LD Micro Invitational on June 3, 2015 2Research Solutions to Present at the LD Micro Invitational on June 3, 2015 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 2Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 3Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 4Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 5Global Pressure Relief Devices Market 2015-2019 2Global Pressure Relief Devices Market 2015-2019 3
... , SAN DIEGO, Oct. 6 NuVasive, Inc. (Nasdaq: ... for minimally disruptive surgical treatments for the spine, announced details ... will take place on Tuesday, October 20, 2009, after the ... conference call on Tuesday, October 20, 2009, at 5:30 p.m. ...
... 6 Physiotherapy Associates, the nation,s foremost provider ... free educational brochure on the benefits of physical ... Physical Therapy Month," as designated by the American ... offers Physiotherapy Associates, 1,500 clinicians a way to ...
Cached Medicine Technology:NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results 2NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results 3Physiotherapy Associates Marks 'National Physical Therapy Month' With Free Educational Brochure 2
... The Monarc Subfascial Hammock™ is ... female patients suffering from stress urinary ... by supporting the urethra during abdominal ... or laughing. Monarc's outside-to-in transobturator approach ...
... innovative architecture of the Uretex® ... and integrity for tension-free sling ... anchors securely to surrounding tissue ... alternate fixation devices, minimizing risk ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
Medicine Products: